View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 10, 2021

Vertex monopoly of the cystic fibrosis space signalled by another label expansion

On 28 April, the European Commission (EC) approved the label expansion for Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor + ivacaftor) for the treatment of cystic fibrosis (CF) in all patients aged 12 years and older who are heterozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation (F), regardless of the other mutation type, either gating (G) or residual function (RF) mutations.

By GlobalData Healthcare

On 28 April, the European Commission (EC) approved the label expansion for Vertex Pharmaceuticals’ Kaftrio (ivacaftor/tezacaftor/elexacaftor + ivacaftor) for the treatment of cystic fibrosis (CF) in all patients aged 12 years and older who are heterozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation (F), regardless of the other mutation type, either gating (G) or residual function (RF) mutations. Kaftrio was first approved on 21 August last year by the EC for CF patients aged 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the CFTR gene.

Free Whitepaper
img

6 Keys to Simplified Labeling Changes in Life Sciences

If you are responsible for managing the change process of labels and related components, or if you’re a stakeholder in the process, you likely have a good understanding of its complexities and challenges. From automated quality checks to organisational change management, leading life sciences label management experts Esko explores here six ways you can simplify label changes and help mitigate the risk of costly – or fatal - labelling errors.
by Esko
Enter your details here to receive your free Whitepaper.

Key opinion leaders (KOLs) interviewed by GlobalData asserted that Kaftrio is the most effective CFTR modulator and that the drug is recommended to nearly all patients once eligible. KOLs further anticipated that eligibility for Kaftrio will gradually expand to more mutations across all ages. While Kaftrio is taking over the CF market, a reasonable concern among developers may be whether there is room for more CFTR modulators. KOLs believe that the CF community supports more options for CFTR modulators in case patients develop intolerances or allergies or experience adverse events. In addition, further competition can drive down drug prices to the benefit of the consumers. The opportunity therefore remains for developers.

There are, however, a couple of challenges that developers should expect to face when entering the CF market. Kaftrio has an established reputation and a firm position in the treatment paradigm. As a result, stable patients are unlikely to risk their condition getting worse by stopping a medication they are responsive to. As well as this, it is hard to recruit patients for new studies of this orphan disease when the majority of the population is already eligible for a marketed CFTR modulator.

CFTR modulators currently in early-stage development include Translate Bio’s MRT-5005 in Phase I/II development, and Eloxx Pharmaceuticals’ ELX-02, AbbVie’s ABBV-3067 alone and in combination with galicaftor (ABBV-2222), Yumanity Therapeutics’ dirocaftor (PTI-808) + nesolicaftor (PTI-428) + posenacaftor (PTI-801), Vertex Pharmaceuticals’ deutivacaftor (VX-561), and VX-121 + tezacaftor + deutivacaftor (VX-561). These are all in Phase II trials.

Vertex currently owns the entire CFTR modulators market share and is expected to remain the market leader over the next decade. But as pipeline products have emerged in early-stage development, Vertex will need to protect its position as market leader in the future. The company’s current strategy of usurping nearly all the market share prior to the launch of any competitors will be a viable strategy to remain the dominant player for the foreseeable future.

Related Companies

Free Whitepaper
img

6 Keys to Simplified Labeling Changes in Life Sciences

If you are responsible for managing the change process of labels and related components, or if you’re a stakeholder in the process, you likely have a good understanding of its complexities and challenges. From automated quality checks to organisational change management, leading life sciences label management experts Esko explores here six ways you can simplify label changes and help mitigate the risk of costly – or fatal - labelling errors.
by Esko
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena